Research programme: human papillomavirus inhibitors - Boehringer Ingelheim
Alternative Names: HPV 11 inhibitors - Boehringer Ingelheim; Human papillomavirus inhibitors research programme - Boehringer IngelheimLatest Information Update: 24 Sep 2012
At a glance
- Originator Boehringer Ingelheim (Canada)
- Class Biphenyl compounds
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Human papillomavirus infections
Most Recent Events
- 18 Sep 2012 Discontinued - Preclinical for Human papillomavirus infections in Canada (unspecified route)
- 06 May 2003 Preclinical trials in Human papillomavirus infections in Canada (unspecified route)